Saturday 17 October 2026
Export RGC’s income statement to Excel — free account
Regencell Bioscience Holdings Limited
RGC Healthcare Drug Manufacturers Specialty & Generic
Dividend growth for three consecutive years.
9.59
0.07
+0.74%
Follow RGC
| Dec '25 | Jun '25 | Jun '24 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
1.42 | 7.38 | 41.91 | 19.15 |
+7 more quarters Free account |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | (1.97) | (0.02) | (0.09) | |
Research and Development Expense of Revenue |
— | — | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
— | — | — | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(2.59) | (3.27) | (4.01) | (4.99) | |
Working Capital |
0.69 | 4.24 | 7.92 | 11.01 | |
Capital Expenditures |
— | (0.15) | (0.01) | (0.03) | |
Net Current Asset Value |
0.56 | 4.01 | 7.89 | 10.99 | |
| Other line items | |||||
Quick Ratio |
1.42 | 7.38 | 41.12 | 19.05 | |
Revenue per Share |
— | — | — | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | |
Average Assets |
9.28 | 11.89 | 14.75 | 6.48 | |
Average Common Equity |
7.95 | 10.97 | 13.96 | 4.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 9 Oct 2026